摘要
原文 | 英語 |
---|---|
期刊 | International Journal of Cancer |
卷 | 131 |
發行號 | 3 |
DOIs | |
出版狀態 | 已發佈 - 八月 1 2012 |
對外發佈 | Yes |
指紋
Keywords
- advanced NSCLC
- EGFR-TKIs
- outcome
- response
- TAM
ASJC Scopus subject areas
- Cancer Research
- Oncology
引用此文
Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. / Chung, Fu Tsai; Lee, Kang Yun; Wang, Chih Wei; Heh, Chih Chen; Chan, Yao Fei; Chen, Huan Wu; Kuo, Chih Hsi; Feng, Po Hao; Lin, Ting Yu; Wang, Chun Hua; Chou, Chun Liang; Chen, Hao Cheng; Lin, Shu Min; Kuo, Han Pin.
於: International Journal of Cancer, 卷 131, 編號 3, 01.08.2012.研究成果: 雜誌貢獻 › 文章
}
TY - JOUR
T1 - Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer
AU - Chung, Fu Tsai
AU - Lee, Kang Yun
AU - Wang, Chih Wei
AU - Heh, Chih Chen
AU - Chan, Yao Fei
AU - Chen, Huan Wu
AU - Kuo, Chih Hsi
AU - Feng, Po Hao
AU - Lin, Ting Yu
AU - Wang, Chun Hua
AU - Chou, Chun Liang
AU - Chen, Hao Cheng
AU - Lin, Shu Min
AU - Kuo, Han Pin
PY - 2012/8/1
Y1 - 2012/8/1
N2 - Our study investigated whether tumor-associated macrophages (TAMs) in advanced non-small cell lung cancer (NSCLC) are related to treatment response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and may be a predictor of survival. Of 206 advanced NSCLC patients treated (first-line) with an EGFR-TKI at the study hospital from 2006 to 2009, 107 with adequate specimens for assessing CD68 immunohistochemistry as a marker of TAMs were assessed. After EGFR-TKI treatment, response was observed in 55 (51%) patients, and the median follow-up period was 13.5 months. Most TAMs were located in the tumor stroma (>95%) and positively costained with the M2 marker CD163. TAM counts were significantly higher in patients with progressive disease than in those without (p <0.0001), a trend that remained in patients with known EGFR mutation status (n = 59) and those with wild-type EGFR (n = 20). High TAM counts, among other factors (e.g., wild-type EGFR), were significantly related to poor progression-free survival (PFS) and overall survival (OS) (all p <0.0001 for TAMs). Multivariate Cox analyses showed that high TAM counts and EGFR mutations were both independent factors associated with PFS [odds ratio (OR), 8.0; 95% confidence interval (CI), 2.87-22.4; p = 0.0001 and OR, 0.03; 95% CI, 0.003-0.31; p = 0.003, respectively] and OS (OR, 2.641; 95% CI, 1.08-6.5; p = 0.03 and OR, 0.14; 95% CI, 0.03-0.56; p = 0.006, respectively). TAMs are related to treatment response irrespective of EGFR mutation and can independently predict survival in advanced NSCLC treated with an EGFR-TKI.
AB - Our study investigated whether tumor-associated macrophages (TAMs) in advanced non-small cell lung cancer (NSCLC) are related to treatment response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and may be a predictor of survival. Of 206 advanced NSCLC patients treated (first-line) with an EGFR-TKI at the study hospital from 2006 to 2009, 107 with adequate specimens for assessing CD68 immunohistochemistry as a marker of TAMs were assessed. After EGFR-TKI treatment, response was observed in 55 (51%) patients, and the median follow-up period was 13.5 months. Most TAMs were located in the tumor stroma (>95%) and positively costained with the M2 marker CD163. TAM counts were significantly higher in patients with progressive disease than in those without (p <0.0001), a trend that remained in patients with known EGFR mutation status (n = 59) and those with wild-type EGFR (n = 20). High TAM counts, among other factors (e.g., wild-type EGFR), were significantly related to poor progression-free survival (PFS) and overall survival (OS) (all p <0.0001 for TAMs). Multivariate Cox analyses showed that high TAM counts and EGFR mutations were both independent factors associated with PFS [odds ratio (OR), 8.0; 95% confidence interval (CI), 2.87-22.4; p = 0.0001 and OR, 0.03; 95% CI, 0.003-0.31; p = 0.003, respectively] and OS (OR, 2.641; 95% CI, 1.08-6.5; p = 0.03 and OR, 0.14; 95% CI, 0.03-0.56; p = 0.006, respectively). TAMs are related to treatment response irrespective of EGFR mutation and can independently predict survival in advanced NSCLC treated with an EGFR-TKI.
KW - advanced NSCLC
KW - EGFR-TKIs
KW - outcome
KW - response
KW - TAM
KW - advanced NSCLC
KW - EGFR-TKIs
KW - outcome
KW - response
KW - TAM
UR - http://www.scopus.com/inward/record.url?scp=84862811913&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862811913&partnerID=8YFLogxK
U2 - 10.1002/ijc.27403
DO - 10.1002/ijc.27403
M3 - Article
C2 - 22174092
AN - SCOPUS:84862811913
VL - 131
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 3
ER -